| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -50.94 M USD | -68.72 M USD | -192.98 M USD | -270.43 M USD | -220.52 M USD | -180.76 M USD | -235.63 M USD | -179.77 M USD | -87.50 M USD | -60.02 M USD | -37.16 M USD | -16.63 M USD |
| Depreciation & Amortization | 2.12 M USD | 5.05 M USD | 4.83 M USD | 5.65 M USD | 9.35 M USD | 8.33 M USD | 7.07 M USD | 3.73 M USD | 956000 USD | 383000 USD | 48000 USD | 6000 USD |
| Stock-Based Compensation | 9.75 M USD | 27.00 M USD | 45.39 M USD | 53.84 M USD | 53.87 M USD | 51.35 M USD | 51.70 M USD | 33.82 M USD | 23.10 M USD | 16.78 M USD | 10.25 M USD | 10.10 M USD |
| Capital Expenditures | 0 USD | 246000 USD | 1.22 M USD | 4.19 M USD | 10.58 M USD | 4.51 M USD | 5.73 M USD | 35.92 M USD | 20.23 M USD | 3.02 M USD | 290000 USD | 46000 USD |
| Cash Flow from Investing | 18.15 M USD | 8.62 M USD | 123.87 M USD | 202.96 M USD | 22.26 M USD | -120.73 M USD | 60.46 M USD | -196.29 M USD | 99.91 M USD | 83.74 M USD | -220.13 M USD | -83.36 M USD |
| Cash Flow from Financing | 16.10 M USD | 59.28 M USD | 2.01 M USD | 53.08 M USD | 103.94 M USD | 427.57 M USD | 188.79 M USD | 357.54 M USD | 20.05 M USD | 506000 USD | 259.23 M USD | 70.27 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -50.94 M USD | -68.96 M USD | -194.20 M USD | -274.62 M USD | -231.10 M USD | -185.27 M USD | -241.36 M USD | -215.70 M USD | -107.73 M USD | -63.05 M USD | -37.45 M USD | -16.67 M USD |
Atara Biotherapeutics Inc. is a biopharmaceutical company focused on developing innovative cell therapies and immunotherapies for patients with serious diseases. The company specializes in creating therapeutic solutions that address critical unmet medical needs across oncology and other disease areas. Atara Biotherapeutics leverages advanced cellular and molecular approaches to design treatments that can potentially offer significant clinical benefits. The company operates in the competitive biopharmaceutical sector, where it collaborates with research institutions, clinical partners, and investors to advance its pipeline of therapeutic candidates through development and regulatory pathways. Founded and headquartered in the United States, Atara Biotherapeutics represents the biotechnology industry's commitment to translating scientific innovation into transformative medical treatments for patients worldwide.